[go: up one dir, main page]

NO20064886L - Immunoglobuliner - Google Patents

Immunoglobuliner

Info

Publication number
NO20064886L
NO20064886L NO20064886A NO20064886A NO20064886L NO 20064886 L NO20064886 L NO 20064886L NO 20064886 A NO20064886 A NO 20064886A NO 20064886 A NO20064886 A NO 20064886A NO 20064886 L NO20064886 L NO 20064886L
Authority
NO
Norway
Prior art keywords
osm
sete
modulate
interaction
immunoglobulins
Prior art date
Application number
NO20064886A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Volker Germaschewski
Alexandre Eon-Duval
Christopher Plumpton
Nicholas Timothy Rapson
Michael Robert West
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0407193A external-priority patent/GB0407193D0/en
Priority claimed from GB0407197A external-priority patent/GB0407197D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20064886L publication Critical patent/NO20064886L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse angår immunglobuliner, for eksempel antistoffer, som spesifikt binder Onkostatin M (OSM), spesielt human OSM (h0SN@11) og modulerer interaksjonen mellom OSM og gpl 30. l typiske utførelsesformer er OSM glykosylert. Oppfinnelsen angår også antistoffer som modulerer interaksjonen mellom både Sete 11 og Sete Ill fra OSM og deres respektive interagerende partnere. Videre er det angitt farmasøytiske blandinger, screening og fremgangsmåter for medisinsk behandling.
NO20064886A 2004-03-30 2006-10-26 Immunoglobuliner NO20064886L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0407193A GB0407193D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
GB0407197A GB0407197D0 (en) 2004-03-30 2004-03-30 Immunoglobulins
PCT/GB2005/001147 WO2005095457A2 (en) 2004-03-30 2005-03-29 Immunoglobulins

Publications (1)

Publication Number Publication Date
NO20064886L true NO20064886L (no) 2006-12-12

Family

ID=35064447

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064886A NO20064886L (no) 2004-03-30 2006-10-26 Immunoglobuliner

Country Status (24)

Country Link
US (2) US7858753B2 (no)
EP (2) EP2404935A1 (no)
JP (1) JP4809828B2 (no)
KR (1) KR100942849B1 (no)
AR (1) AR048516A1 (no)
AT (1) ATE515515T1 (no)
AU (1) AU2005229457B2 (no)
BR (1) BRPI0509367A (no)
CA (1) CA2562953A1 (no)
CY (1) CY1112192T1 (no)
DK (1) DK1730191T3 (no)
HR (1) HRP20110657T1 (no)
IL (1) IL178119A0 (no)
MA (1) MA28541B1 (no)
NO (1) NO20064886L (no)
NZ (1) NZ550225A (no)
PE (1) PE20060287A1 (no)
PL (1) PL1730191T3 (no)
PT (1) PT1730191E (no)
RU (5) RU2429245C2 (no)
SG (1) SG151292A1 (no)
SI (1) SI1730191T1 (no)
TW (1) TWI365746B (no)
WO (1) WO2005095457A2 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
WO2007098547A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
EA017303B1 (ru) 2006-05-25 2012-11-30 Глаксо Груп Лимитед Модифицированные гуманизированные антитела против интерлейкина-18 и их применение
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
PT2305300E (pt) 2008-07-10 2016-06-16 Toray Industries Composição farmacêutica para o tratamento e prevenção do cancro
CN102170907A (zh) 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
JP2012501178A (ja) * 2008-08-26 2012-01-19 マクロジェニクス，インコーポレーテッド Ｔ細胞受容体抗体およびその使用方法
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
EP2258723A1 (en) * 2009-06-02 2010-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of oncostatin M receptor ß mediated heart failure
CN102834113B (zh) 2010-02-04 2016-03-02 东丽株式会社 癌的治疗和/或预防用药物组合物
CA2788718C (en) 2010-02-04 2019-05-21 Shinichi Kobayashi Caprin-1 antibody for treating and/or preventing cancer
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR101801667B1 (ko) 2010-02-04 2017-11-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
ES2543174T3 (es) 2010-02-04 2015-08-17 Toray Industries, Inc. Composición medicinal para el tratamiento y/o la prevención del cáncer
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
CA2814652C (en) 2010-10-13 2021-05-18 Janssen Biotech, Inc. Human oncostatin m antibodies and methods of use
TWI504609B (zh) 2010-11-23 2015-10-21 Glaxo Group Ltd 抗原結合蛋白質
ES2609859T3 (es) 2011-08-04 2017-04-24 Toray Industries, Inc. Composición de fármaco para el tratamiento y/o la prevención del cáncer
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
US9180188B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
MX357505B (es) 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CN104114581B (zh) 2012-02-21 2018-11-30 东丽株式会社 癌的治疗和/或预防用药物组合物
EP2818482B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
RU2633505C2 (ru) 2012-02-21 2017-10-12 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
US9416193B2 (en) 2012-03-30 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
RU2649802C2 (ru) 2012-03-30 2018-04-04 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
EP3456743B1 (en) 2013-05-30 2021-08-18 Kiniksa Pharmaceuticals, Ltd. Oncostatin m receptor antigen binding proteins
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
KR102056963B1 (ko) 2013-12-30 2019-12-17 에피맙 바이오테라퓨틱스 인코포레이티드 Fabs-인-탠덤 면역글로불린 및 이의 용도
CR20160444A (es) * 2014-02-24 2017-04-21 Takeda Gmbh Proteínas de fusión uti
WO2016046738A1 (en) * 2014-09-24 2016-03-31 Università Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
EP3250925B1 (en) * 2015-01-29 2019-04-10 Ares Trading S.A. Immunoassays for highly positively charged proteins
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
WO2017170334A1 (ja) 2016-03-28 2017-10-05 東レ株式会社 癌の治療及び／又は予防用医薬組成物
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
CN112074541A (zh) 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
AU2021364308A1 (en) 2020-10-19 2023-05-18 Zoetis Services Llc Antibodies to canine and feline oncostatin m receptor beta and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
EP1266965B1 (en) 1991-07-25 2006-05-24 Biogen Idec Inc. Recombinant antibodies for human therapy
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
JP3622208B2 (ja) 1993-06-11 2005-02-23 東ソー株式会社 骨粗鬆症治療方法及び治療薬
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
EP1073464B1 (en) 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells

Also Published As

Publication number Publication date
RU2011121419A (ru) 2012-12-10
BRPI0509367A (pt) 2007-09-11
KR100942849B1 (ko) 2010-02-17
KR20060135049A (ko) 2006-12-28
EP1730191B1 (en) 2011-07-06
AR048516A1 (es) 2006-05-03
EP2404935A1 (en) 2012-01-11
US7858753B2 (en) 2010-12-28
PL1730191T3 (pl) 2011-12-30
AU2005229457A1 (en) 2005-10-13
MA28541B1 (fr) 2007-04-03
JP2007530068A (ja) 2007-11-01
IL178119A0 (en) 2006-12-31
RU2006134477A (ru) 2008-05-10
WO2005095457A2 (en) 2005-10-13
RU2009108147A (ru) 2010-09-20
NZ550225A (en) 2010-11-26
DK1730191T3 (da) 2011-10-17
AU2005229457B2 (en) 2010-11-25
TWI365746B (en) 2012-06-11
JP4809828B2 (ja) 2011-11-09
RU2009108148A (ru) 2010-09-20
RU2429245C2 (ru) 2011-09-20
PE20060287A1 (es) 2006-05-16
US20110245470A1 (en) 2011-10-06
US20070286861A1 (en) 2007-12-13
TW200602079A (en) 2006-01-16
SG151292A1 (en) 2009-04-30
RU2009108149A (ru) 2010-09-20
ATE515515T1 (de) 2011-07-15
WO2005095457A3 (en) 2006-04-27
CY1112192T1 (el) 2015-12-09
PT1730191E (pt) 2011-10-04
HRP20110657T1 (hr) 2011-10-31
SI1730191T1 (sl) 2011-11-30
CA2562953A1 (en) 2005-10-13
HK1103747A1 (en) 2007-12-28
EP1730191A2 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
NO20064886L (no) Immunoglobuliner
CR20140239A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (divisional de 2013-0351)
NO20091264L (no) Anti-myostatin antistoffer
MX2007000023A (es) Anticuerpos del receptor uno de interferon alfa, y sus usos.
NO20085362L (no) Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet
EA201100694A1 (ru) Антитело к cd38 человека и его применение
GEP20104922B (en) Antibodies to m-csf
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
NO20063569L (no) M-CSF-spesifikt monoklonalt antistoff og anvendelse derav
NO20052769L (no) Enkeldomene antistoffer rettet mot tumor nekrose faktor-alfa og anvendelser derav
ATE461178T1 (de) Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden
EP2363404A3 (en) PSMA antibodies
UA92504C2 (en) Anti-myostatin monoclonal antibody
DE602006013029D1 (de) Anti-egfr-antikörper
NO20081421L (no) Midler for hindring og behandling av forstyrrelser som involverer modulering av RYR-reseptorer
NO20060812L (no) Et CA6-antigenspesifikt konjugat og fremgangsmater for andvendelse av det samme
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
NO20074002L (no) Androgen reseptor-modulatorforbindelser og fremgangsmater
PL1608399T3 (pl) Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu
NO20083050L (no) Forbindelser og fremgangsmater for hemming av interaksjon av Bcl-proteiner med bindingspartnere
ZA202408121B (en) Anti-human il-4ra antibody and application thereof
NO20075321L (no) Fremgangsmate for bronnbehandling og konstruksjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application